1-piperidinyl-(5-thiophen-2-yl-3-isoxazolyl)methanone

1-Piperidinyl-(5-thiophen-2-yl-3-isoxazolyl)methanone, also known as **JNJ-54175859**, is a potent and selective **inhibitor of the enzyme histone deacetylase 6 (HDAC6)**.

Here's why it's important for research:

* **HDAC6 and its role in various diseases:** HDAC6 is a key enzyme involved in regulating the acetylation of proteins, particularly tubulin, which plays a vital role in cell structure and function. HDAC6 inhibition has been shown to have potential therapeutic benefits in a variety of diseases, including:
* **Cancer:** By inhibiting HDAC6, JNJ-54175859 can promote the accumulation of acetylated tubulin, leading to microtubule stabilization and cell death in cancer cells.
* **Neurodegenerative diseases:** HDAC6 inhibition can potentially protect against neurodegeneration by promoting neuronal survival and reducing inflammation.
* **Inflammation:** HDAC6 inhibition can modulate inflammatory responses and potentially benefit inflammatory conditions.

* **JNJ-54175859 as a potential drug candidate:** JNJ-54175859 exhibits high potency and selectivity for HDAC6, making it a promising drug candidate for the treatment of these diseases. Its preclinical studies have shown promising results, demonstrating its efficacy in reducing tumor growth and improving neurological function in animal models.

* **Research tool for understanding HDAC6 function:** JNJ-54175859 serves as a valuable tool for researchers to study the role of HDAC6 in various biological processes. It allows scientists to investigate the effects of HDAC6 inhibition on cell function, signaling pathways, and disease progression.

**However, it's crucial to note that JNJ-54175859 is currently in preclinical development, and it's still under investigation. More research is needed to fully understand its safety and efficacy in humans before it can be used as a therapeutic agent.**